Acquisition Opportunity FlowJo has recently been acquired by Waters Corporation as of February 2026, presenting a potential collaboration or integration opportunity with Waters’ analytics platforms and BD Biosciences assets to expand product reach, cross-sell capabilities, and align with Waters’ global life sciences portfolio.

Single-Cell Focus With a long track record in flow cytometry and single-cell data analysis, FlowJo’s software is central to phenotyping and immunology research. This positions BD and Waters customers who require advanced single-cell workflows as a key market for expanded licensing, modules, or cloud-based services.

Mid-Mized Scale FlowJo operates with a lean team (11-50 employees) and annual revenue in the multi-million range. This suggests a strong opportunity for value-based pricing, scalable support packages, and partner-led selling to accelerate onboarding of mid-sized research labs and contract research organizations.

Strategic Location Based between Portland and San Francisco with proximity to premier research hubs, FlowJo can leverage regional presence for field engineering, training programs, and co-hosted events with Waters’ distribution network to drive awareness and trial adoption among top-tier institutions.

Expansion via Cloud and Partnerships Past product launches such as FlowJo Envoy and collaboration efforts indicate appetite for cloud-enabled workflows and consulting partnerships. This creates upsell opportunities for cloud-based analytics, data orchestration, and managed services aligned with Waters’ informatics ecosystem.